Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.750-0.80 for the period, compared to the consensus EPS estimate of 0.740. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.

Analyst Ratings Changes

Several research analysts have recently weighed in on AMRX shares. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their target price on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Amneal Pharmaceuticals Trading Up 1.4%

Shares of AMRX stock opened at $10.43 on Thursday. Amneal Pharmaceuticals has a 12 month low of $6.68 and a 12 month high of $10.68. The stock has a market cap of $3.28 billion, a P/E ratio of 1,044.04 and a beta of 1.18. The company has a 50 day simple moving average of $9.92 and a two-hundred day simple moving average of $8.60.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Monday, July 21st. The company reported $0.21 earnings per share for the quarter. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. The business had revenue of $695.42 million for the quarter. Amneal Pharmaceuticals has set its Q2 2025 guidance at EPS. As a group, equities analysts forecast that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, EVP Andrew S. Boyer sold 279,244 shares of the company’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total value of $2,619,308.72. Following the completion of the sale, the executive vice president owned 152,426 shares in the company, valued at $1,429,755.88. This represents a 64.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John Kiely sold 32,000 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total value of $295,360.00. Following the transaction, the director directly owned 225,433 shares in the company, valued at approximately $2,080,746.59. The trade was a 12.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 609,206 shares of company stock worth $5,700,625. Company insiders own 26.56% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. State of Tennessee Department of Treasury purchased a new stake in shares of Amneal Pharmaceuticals in the second quarter worth $133,000. Rafferty Asset Management LLC boosted its holdings in Amneal Pharmaceuticals by 22.0% in the 2nd quarter. Rafferty Asset Management LLC now owns 16,984 shares of the company’s stock worth $137,000 after buying an additional 3,066 shares during the period. Tower Research Capital LLC TRC increased its stake in Amneal Pharmaceuticals by 510.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,768 shares of the company’s stock worth $144,000 after buying an additional 14,855 shares in the last quarter. Creative Planning raised its holdings in Amneal Pharmaceuticals by 61.9% during the second quarter. Creative Planning now owns 23,896 shares of the company’s stock valued at $193,000 after acquiring an additional 9,136 shares during the period. Finally, Headlands Technologies LLC lifted its position in shares of Amneal Pharmaceuticals by 570.1% in the second quarter. Headlands Technologies LLC now owns 24,692 shares of the company’s stock valued at $200,000 after acquiring an additional 21,007 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.